Oisin Biotechnologies Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
17
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$15M
- Investors
-
21
Oisin Biotechnologies General Information
Description
Developer of senolytic therapy technology designed to develop genetic medicines to address age-related diseases. The company's lead program targets frailty by stimulating muscle growth, independent of exercise, its second program selectively kills fat cells, and we have a robust pipeline targeting multiple drivers of age-related conditions, its therapies leverage a new, non-viral delivery technology with extensive extrahepatic biodistribution for both DNA (deoxyribonucleic acid) and RNA (ribonucleic acid) payloads, enabling clinicians to combat age-related diseases.
Contact Information
Website
www.oisinbio.comCorporate Office
- 701 Fifth Avenue
- Suite 4200
- Seattle, WA 98104
- United States
Corporate Office
- 701 Fifth Avenue
- Suite 4200
- Seattle, WA 98104
- United States
Oisin Biotechnologies Timeline
Oisin Biotechnologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series A) | 28-Jun-2024 | $15M | Completed | Generating Revenue | ||
| 3. Later Stage VC | 01-Dec-2022 | Completed | Generating Revenue | |||
| 2. Seed Round | 27-May-2021 | $9.5M | $10M | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 22-Mar-2017 | $500K | $500K | Completed | Startup |
Oisin Biotechnologies Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-1 | ||||||||
| Series A | ||||||||
| Seed-1 | 5,914,443 | $0.000100 | 6% | $2.41 | $2.41 | 1x | $2.41 | 25.07% |
| Seed | 1,127,660 | $0.000100 | 6% | $0.1 | $0.1 | 1x | $0.1 | 4.78% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Oisin Biotechnologies Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Oisin Biotechnologies Patents
Oisin Biotechnologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3233729-A1 | Compositions and methods for liver-specific expression of follistatin | Pending | 01-Oct-2020 | ||
| EP-4408997-A2 | Compositions and methods for liver-specific expression of follistatin | Pending | 01-Oct-2020 | ||
| US-20240374760-A1 | Compositions and methods for liver-specific expression of follistatin | Pending | 01-Oct-2020 | ||
| US-20220106608-A1 | Fusogenic lipid nanoparticles for the target cell-specific production of rapamycin inducible therapeutic proteins | Pending | 04-Feb-2019 | ||
| EP-3920888-A2 | Fusogenic lipid nanoparticles for the target cell-specific production of rapamycin inducible therapeutic proteins | Pending | 04-Feb-2019 | C12N15/85 |
Oisin Biotechnologies Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Oisin Biotechnologies Investors (21)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AbbVie Ventures | Corporate Venture Capital | Minority | ||
| IKJ Capital | Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| LongGame | Venture Capital | Minority | ||
| Methuselah Foundation | Not-For-Profit Venture Capital | Minority |
Oisin Biotechnologies FAQs
-
When was Oisin Biotechnologies founded?
Oisin Biotechnologies was founded in 2014.
-
Where is Oisin Biotechnologies headquartered?
Oisin Biotechnologies is headquartered in Seattle, WA.
-
What is the size of Oisin Biotechnologies?
Oisin Biotechnologies has 17 total employees.
-
What industry is Oisin Biotechnologies in?
Oisin Biotechnologies’s primary industry is Biotechnology.
-
Is Oisin Biotechnologies a private or public company?
Oisin Biotechnologies is a Private company.
-
What is the current valuation of Oisin Biotechnologies?
The current valuation of Oisin Biotechnologies is .
-
What is Oisin Biotechnologies’s current revenue?
The current revenue for Oisin Biotechnologies is .
-
How much funding has Oisin Biotechnologies raised over time?
Oisin Biotechnologies has raised $25.4M.
-
Who are Oisin Biotechnologies’s investors?
AbbVie Ventures, IKJ Capital, , LongGame, and Methuselah Foundation are 5 of 21 investors who have invested in Oisin Biotechnologies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
